Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Abbott to Separate into 2 Companies
October 21, 2011
- Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
- No. of Latuda Prescriptions to Potentially Exceed Forecast: Nomura Securities
October 21, 2011
- Takeda Positions “Enbrel MRs” in Boosted Cooperation Efforts with Pfizer
October 20, 2011
- Otsuka to Set Up Joint Venture Company to Develop, Commercialize Pancreatic Islet Cells
October 20, 2011
- Growell to Introduce T-Point Service for Copayments of Ethical Drugs
October 20, 2011
- Sanofi Signs Comprehensive Contract with Kyoto Univ. on Life Science Research
October 19, 2011
- Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
- JT to Cease Development of Osteoporosis Treatment following Termination of License Agreement with Merck
October 19, 2011
- UCB Japan Reorganizes Sales & Marketing Division to Enhance Specialization
October 19, 2011
- SSP Aims for 10% Market Share with Switch OTC Alesion 10
October 19, 2011
- Japan, a Strategic Country Where Growth is Expectable: New AZ President Hudson
October 18, 2011
- MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
- MTPC Aims to Initiate Clinical Studies for 3 Compounds per Year
October 18, 2011
- Torii Upwardly Revises Profit Forecast for 1st Half of FY2012
October 18, 2011
- Eisai, Johns Hopkins Univ. Agree on Neurological Drug Discovery Collaboration
October 18, 2011
- OncoTherapy Science to Start Clinical Trial for Cancer Treatment Antibody in France
October 18, 2011
- Takeda Appoints Davidsen Head of Emerging Markets, Nycomed
October 18, 2011
- R-Tech Ueno to Resume Development of Treatment for Dry Eye
October 18, 2011
- NBI, Eli Lilly Japan to Establish “Special Position” for Trazenta in DPP-4 Inhibitor Market
October 18, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…